Navigation Links
NPS Reports Successful GATTEX(TM) Extension Study
Date:3/17/2008

Top-Line Data Confirm Pivotal Study Findings

BEDMINSTER, N.J., March 17 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today reported positive top-line results from a 28-week blinded Phase 3-extension study of GATTEX(TM) (teduglutide) for short bowel syndrome (SBS) patients who are dependent upon parenteral nutrition (PN). The extension study enrolled 65 of the 71 patients (91%) who had completed a 24-week randomized Phase 3 study that evaluated low-dose GATTEX (0.05 mg/kg/day) and high-dose GATTEX (0.10 mg/kg/day) versus placebo.

The primary objective of the Phase 3 extension study was to evaluate the long-term safety and tolerability of daily GATTEX dosing for up to 52 weeks (24-week Phase 3 study and 28-week extension study). Overall, both doses of GATTEX were safe and generally well-tolerated, with no statistical differences in the incidence rate of adverse events or serious adverse events among the treatment groups when compared to placebo-treated patients in the Phase 3 study, with the exception of injection site reactions, which were higher in the high-dose GATTEX dose. A number of efficacy measures were also included as a secondary endpoint of the extension study. The company expects full results from the Phase 3-extension study to be presented at a future medical meeting.

Key efficacy findings included:

-- Sixty-eight percent (68%) of the 25 patients who had received low-dose

GATTEX therapy and continued on low-dose GATTEX, and fifty-two percent

(52%) of the 27 patients who had received high-dose GATTEX therapy and

continued on high-dose GATTEX achieved a 20% or greater reduction in PN

after a total of 52 weeks of therapy.

'/>"/>
SOURCE NPS Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... RMD ) today announced results for its quarter ended ... a 10 percent increase compared to the quarter ended December ... basis). Net income was $91.2 million, an increase of 5 ... earnings per share for the quarter were $0.64, an increase ...
(Date:1/22/2015)...  Profil Institute for Clinical Research, Inc., a clinical research ... a new textbook,  Translational Research Methods for Diabetes, Obesity ... global scientific publisher. The textbook is the ... in early phase clinical studies of new drugs for ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ( ... Diagnostics Market by Allergen Source, Product & by End User ... The global allergy diagnostics market is valued ... at a CAGR of 12.67%, to reach $2,230.72 million by ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... 7, 2011  Inovio Pharmaceuticals, Inc. (NYSE Amex: ... cancers and infectious diseases, announced today that it has ... its common stock and warrants to purchase up to ... the partial exercise of the underwriter,s overallotment option to ...
... FRANCISCO, Calif., Dec. 6, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... a teleconference and webcast to reprise key carfilzomib data presentations ... (ASH) Annual Meeting in San Diego, California. The ... 2011.  Interested parties may access the teleconference ...
Cached Medicine Technology:Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 2Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 3Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 4
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and easy ... treat specific body parts and muscle groups. , IsoComforter, ... use patented cold therapy machine with the innovative IsoTube design ... injuries. IsoComforter has become the industry leader in cold ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the ... in an effort to further promote visibility and adoption of ... long made AMA journals available via its subscription services, EBSCO ... Network. , Long known as both a subscription ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a list ... policy . , Some types of vehicles cannot be covered ... released blog post to see if their vehicle qualifies for auto ... some of the cars that cannot be covered by a plan. ...
(Date:1/22/2015)... State Forestry Institute of Mecklenburg-Vorpommern in Germany ... from GEOSYSTEMS, a dedicated Hexagon Geospatial and Intergraph partner ... Geospatial’s ERDAS APOLLO for cataloging, managing, and ... clouds and documents. This effort will enable the State ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... today inaugurated a new 120-bed drug de-addiction centre with a ... of Asia’s biggest prisons having over 13,000 inmates. The ... built at a cost of Rs.17 million. ... started in any jail in the country for treatment, post-treatment ...
... of chromium as the shiny metal in the bumpers of ... a crucial role in human health//, reports Harvard Men’s Health ... deficiency leads to high cholesterol levels. In humans, the results ... early to recommend chromium supplements for cholesterol. But there may ...
... recent study suggest that - Telephone outreach can dramatically ... in an urban minority// population, constituting predominantly of black ... that black minority does not believe in getting regular ... conducted regularly via three day stool blood test, reduces ...
... 50% of the HIV infection rate among heterosexual men has ... seeking it.// , ,2,500 Ugandan males were ... nearly half were adults. Less than 400 adult males were ... that new HIV infections among circumcised heterosexual men in Uganda ...
... uncovered the possible causes for brain disorders such as ... November 1, 2006 in the prestigious journal Nature Neuroscience. ... regional blood flow changes in the brain. To function ... of oxygen and glucose, which is provided through an ...
... a customised personal digital assistant (PDA) to dramatically ... said Thursday. ,Instead of fumbling with ... speech impairments express their needs in such everyday ... attention from an archive of commonly-used phrases and ...
Cached Medicine News:Health News:Chromium May Help Diabetes, Cholesterol, and Heart Disease 2Health News:Telephone Outreach Boost CRC Screening In Urban Minority 2Health News:Potential Key to Brain Blood-Flow Disorders Explored by Scientists 2Health News:Potential Key to Brain Blood-Flow Disorders Explored by Scientists 3Health News:Potential Key to Brain Blood-Flow Disorders Explored by Scientists 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: